Send to

Choose Destination
Br J Haematol. 2016 Nov;175(4):724-732. doi: 10.1111/bjh.14298. Epub 2016 Sep 8.

A rapid, inexpensive and disposable point-of-care blood test for sickle cell disease using novel, highly specific monoclonal antibodies.

Author information

Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Silver Lake Research Corporation, Azusa, CA, USA.


Sickle cell disease (SCD) is a significant healthcare burden worldwide, but most affected individuals reside in low-resource areas where access to diagnostic testing may be limited. We developed and validated a rapid, inexpensive, disposable diagnostic test, the HemoTypeSC , based on novel monoclonal antibodies (MAbs) that differentiate normal adult haemoglobin (Hb A), sickle haemoglobin (Hb S) and haemoglobin C (Hb C). In competitive enzyme-linked immunosorbent assays, each MAb bound only its target with <0·1% cross-reactivity. With the HemoTypeSC test procedure, the sensitivity for each variant was <5·0 g/l. The accuracy of HemoTypeSC was evaluated on 100 whole blood samples from individuals with common relevant haemoglobin phenotypes, including normal (Hb AA, N = 20), carrier or trait (Hb AS, N = 22; Hb AC, N = 20), SCD (Hb SS, N = 22; Hb SC, N = 13), and Hb C disease (Hb CC, N = 3). The correct haemoglobin phenotype was identified in 100% of these samples. The accuracy of the test was not affected by Hb F (0-94·8% of total Hb) or Hb A2 (0-5·6% of total Hb). HemoTypeSC requires <1 μl of whole blood and no instruments or power sources. The total time-to-result is <20 min. HemoTypeSC may be a practical solution for point-of-care testing for SCD and carrier status in low-resource settings.


haemoglobinopathy; lateral flow immunoassay; monoclonal antibody; point of care; sickle cell disease

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center